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Introduction
Antinuclear antibodies (ANAs) are present in many patients with autoimmune disease and in essentially 
all patients with systemic lupus erythematosus (SLE). We and others have shown that B cells reactive with 
nuclear antigens (ANA+ B cells) are censored during B cell maturation (1–5). This censoring occurs in 
SLE patients as well as in healthy individuals (1, 2). We previously identified a major tolerance checkpoint 
for ANA+ IgG+ plasma cells/plasmablasts (hereafter commonly referred to as PCs) in nonautoimmune 
mice and healthy individuals that is attenuated in SLE patients and in lupus-prone mice (2). In SLE, this 
correlates with an overall enhanced IgG+ PC differentiation, resulting in an increase in ANA+ IgG PCs in 
SLE, rather than an antigen-specific selection defect. Although the percentage of  IgG PCs that are ANA+ 
is the same as in healthy controls, there are more IgG PCs in SLE patients.
PCs may arise through 2 main pathways: germinal center (GC) or extrafollicular; both have been 
implicated in the autoantibody production in SLE (6, 7). GC responses are well known to be increased in 
lupus-prone mice, and some SLE patients have increased numbers of  circulating pre-GC B cells, switched 
memory B cells and T follicular helper (Tfh) cells, suggestive of  enhanced GC responses (8–10). Given 
that many IgG anti-DNA autoantibodies, which are considered to be pathogenic in SLE, show evidence 
of  somatic hypermutation (SHM) (11), the production of  autoreactive PCs by SHM of  nonautoreactive 
naive B cells within the GC has been considered to be an important contributor to the development of  
SLE in both mice (12) and humans (13) In contrast, extrafollicular PC differentiation in autoimmunity 
has not been emphasized, although recent studies indicate this pathway may also contribute to SLE (6, 
14, 15). MRL/lpr mice exhibit extrafollicular PC generation, although they have increased formation of  
spontaneous GCs as well (8, 14, 16). In humans, recent research demonstrates that a large proportion 
of  the PCs in some SLE patients are clonally related to naive cells rather than IgG+ memory B cells, 
suggesting an extrafollicular origin (6).
IgG antinuclear antibodies (ANAs) are a dominant feature of several autoimmune diseases. 
We previously showed that systemic lupus erythematosus (SLE) is characterized by 
increased ANA+ IgG plasmablasts/plasma cells (PCs) through aberrant IgG PC differentiation 
rather than an antigen-specific tolerance defect. Here, we aimed to understand the 
differentiation pathways resulting in ANA+ IgG PCs in SLE patients. We demonstrate distinct 
profiles of ANA+ antigen-experienced B cells in SLE patients, characterized by either a 
high frequency of PCs or a high frequency of IgG+ memory B cells. This classification of 
SLE patients was unrelated to disease activity and remained stable over time in almost all 
patients, suggesting minimal influence of disease activity. A similar classification applies to 
antigen-specific B cell subsets in mice following primary immunization with T-independent 
and T-dependent antigens as well as in lupus-prone mouse models (MRL/lpr and NZB/W). 
We further show that, in both lupus-prone mice and SLE patients, the classification 
correlates with the serum autoantibody profile. In this study, we identified B cell phenotypes 
that we propose reflect an extrafollicular pathway for PC differentiation or a germinal center 
pathway, respectively. The classification we propose can be used to stratify patients for 
longitudinal studies and clinical trials.
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Because there are no definitive markers that discriminate PCs based on their pathway of  differenti-
ation, it is hard to establish the pathway through which they were derived, especially in humans where 
access to lymphoid organs is limited. In addition, most studies discriminating extrafollicular responses 
from GC responses use acute immunization models, and it is not clear if  all the paradigms that have been 
proposed for the distinction between extrafollicular and GC responses apply in the chronic immune activa-
tion present in autoimmune conditions.
Here, we aimed to understand the differentiation pathways resulting in ANA+ IgG PCs in SLE patients. 
Using our flow cytometry–based assay for ANA+ B cells and PCs, we have identified 3 patterns of  ANA+ 
antigen-experienced B cells. We now propose a classification of  patients based on the relative frequency of  
ANA+ memory B cells and PCs.
By correlating this classification with primary immune responses in nonautoimmune mice and the 
autoimmune response in lupus-prone mice, we identified one pattern that we propose reflects an extrafollic-
ular pathway for PC differentiation and another pattern that reflects a GC pathway. Furthermore, we show 
that, in the majority of  patients, the pattern is stable over time and correlates with antigen recognition by 
serum autoantibodies.
Results
Distinct phenotypes of  ANA+ antigen-experienced B cells in SLE patients. We recently reported that a major B 
cell abnormality in SLE patients is an increase in total and ANA+ IgG PCs, measured using a flow cyto-
metric assay that determined the frequency of  transitional, naive, switched, and unswitched memory cells 
and IgM and IgG PCs and the proportion of  ANA+ cells within each subset (2). Here, we were interested 
in whether this analysis could help refine our understanding of  the differences between healthy subjects 
and SLE patients and characterize the heterogeneity of  SLE patients. We expanded our cohort to 36 SLE 
patients and confirmed that the frequency of  ANA+ IgG PCs and total IgG PCs was significantly increased 
in SLE patients compared with healthy controls, whereas no significant differences were observed among 
the other B cell subsets (Figure 1, A–F, and Supplemental Figure 1, A–D; supplemental material available 
online with this article; https://doi.org/10.1172/jci.insight.127885DS1). Demographic characteristics of  
the SLE patients and healthy subjects were not significantly different, except for ethnicity (Supplemental 
Table 1). We observed a large spread in the frequency of  ANA+ IgG PCs in SLE patients. A proportion 
of  patients (~40%) did not demonstrate increased frequencies of  ANA+ IgG PCs compared with healthy 
subjects (using a nonparametric cutoff  for the frequency of  ANA+ IgG PCs in healthy subjects (quartile 3 + 
1.5 × interquartile range within the healthy subjects) (Figure 1E). We designated these patients as cluster 0.
We performed a principal component analysis, based on all flow cytometry B cell parameters studied 
(percentages of  total and ANA+ transitional, naive, IgG memory, IgM, and IgG PCs) to analyze clustering 
of  SLE patients and healthy subjects in a nonbiased way and to see if  we could use these parameters to 
stratify the SLE patients (Figure 1, G and H). Cluster 0 patients, without PC expansion, overlapped largely 
with the healthy controls (Figure 1, G and H). The cluster 0 phenotype was not related to clinical param-
eters such as disease activity or medication (Supplemental Table 2). Although there are no suggestions of  
active ongoing ANA+ PC differentiation in blood of  individuals within cluster 0, the proportion of  patients 
with anti-dsDNA positivity and the range of  anti-DNA titers was similar to that of  the patients with circu-
lating PC expansion, suggesting that serum autoantibodies in cluster 0 may be derived from long-lived PCs 
residing in the bone marrow or other tissues. To understand pathways of  PC differentiation in SLE, we next 
focused on SLE patients with significantly higher numbers of  circulating ANA+ PCs.
The frequencies of  ANA+ and total IgM and IgG PCs all contributed strongly to principal component 
1 (Figure 1G), which was the main discriminator for SLE patients without or with PC expansion (Figure 
1H). Another main contributor to principal component 1 was the IgG+ memory B cell subset (Figure 1G). 
Importantly, in SLE patients with an expansion of  ANA+ IgG PCs, the memory B cells and PCs are pres-
ent in inverse frequency, such that the patients with the highest ANA+ PC numbers generally have lower 
numbers of  ANA+ memory B cells and vice versa, leading to opposing vectors for PCs and memory B cells 
in the principal component analysis (Figure 1, G and I). To assess these 2 groups of  patients and enable a 
classification paradigm, patients were grouped based on ANA+ IgM and IgG PCs relative to ANA+ memo-
ry B cells. A 20% cutoff  for the relative proportion of  ANA+ PCs among ANA+ antigen-experienced B cells 
(PCs and memory cells) was chosen to distinguish cluster 1 (>20% ANA+ PCs compared with ANA+ IgG 
memory B cells) from cluster 2 (<20% ANA+ PCs compared with ANA+ IgG memory B cells) (Figure 1J). 
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Using this cutoff, the principal component analysis showed a separation of  the 2 groups of  patients 
with expansion of  circulating ANA+ PCs (Figure 1K). Approximately one-third of  the patients with an 
expansion of  ANA+ PCs showed a cluster 1 phenotype, whereas the remaining two-thirds of  the patients 
belonged to cluster 2.
Interestingly, although it has been reported that patients with active disease have increases in total PC 
frequency (17), the clustering seemed independent of  SLE disease activity index (SLEDAI) scores, which 
overlapped in all 3 groups (Figure 1J and Supplemental Table 2), and we did not observe a correlation of  
SLEDAI with the frequency of  total IgG PCs or ANA+ IgG PCs (data not shown). Furthermore, when 
including only patients with active disease (SLEDAI >4), the same clustering was observed (data not 
shown). Patients from cluster 2 were less likely to be on steroids (Supplemental Table 2), although each 
cluster contained patients that did not use this medication.
There is a conflict in the literature as to whether SLE autoreactivity is a consequence of  activation of  
naive cells into PCs directly through an extrafollicular pathway or via activation of  a GC response with 
generation of  both memory B cells and PCs. Our data suggest that there are 2 clusters of  SLE patients with 
an expanded proportion of  PCs, 1 of  which has a high and 1 a low frequency of  ANA+ memory B cells. 
We believe that a cutoff  of  20% although arbitrary, provides a simple method to define and classify patients 
based on the relative proportions of  ANA+ antigen-experienced B cell subsets.
Phenotype of  ANA+ B cells and PCs in SLE patients is stable over time. Clinical data suggested that there 
is no clear correlation of  the cellular phenotypes with disease activity, or other patient characteristics, 
except steroid use; nonetheless, we sought to establish the stability of  the classification over time. This is 
particularly important, as T-dependent immune responses, such as in response to vaccination or infection, 
are usually characterized by an initial wave of  PCs derived from an extrafollicular response, followed by 
GC response with IgG+ memory B cells and PCs. Therefore, a response that is characterized initially by 
large numbers of  PCs might develop into a response dominated by memory B cells over time, in particular 
when the initial analysis is done during a clinical flare. Using our classification paradigm, 13 patients 
were reassessed between 1 and 12 months after their initial assessment (Figure 2A). Of  the 5 patients from 
cluster 1 that were analyzed twice, 4 remained in this cluster over a time period ranging from 2 months to 
1 year, demonstrating that individuals in this cluster do not routinely progress to a cluster 2 classification. 
Of  the 6 patients from cluster 2 with repeat analyses occurring from 1 month to 1 year, 5 showed the same 
classification. Two patients in cluster 0 were analyzed a second time and both maintained the same ratio 
of  memory to PCs. Furthermore, using the principal components identified in Figure 1 to analyze the 
repeat assessments showed similar clustering of  the individual patients (Figure 2B). Even the 2 patients 
whose classification based on the relative frequency of  ANA+ PCs relative to ANA+ memory cells changed 
(black dotted arrows) generally fell within the same area on the principal component analysis plot (Figure 
2B). Importantly, all patients with considerable changes in disease activity (change in SLEDAI ≥5) (SLE 
01, SLE 05, SLE 25, SLE 32) and clinical features of  disease (SLE 01, SLE 05, SLE 07, SLE 25) and all 
patients who had a flare during one of  the measurements (SLE 05, SLE 07, SLE 32), except one (SLE19), 
retained the same classification, and almost all subjects with a considerable change in medications (SLE 
01, SLE 05, SLE 07, SLE 09, SLE 25, SLE 32) also preserved their cluster classification (Figure 2A and 
Supplemental Table 3). Two patients in cluster 2 started using PDN (SLE 01, SLE 09), but each retained 
the same classification, suggesting that the more frequent use of  PDN in cluster 1 patients was not directly 
affecting their clustering.
These data suggest that although the classification scheme is necessarily arbitrary, the vast majority of  
patients (85%) show stability of  their classification, further confirming the robustness of  our ANA assay. 
Moreover, the relative proportions of  autoreactive memory B cells and PCs in SLE patients seems imprinted, 
possibly by genetic risk factors.
Classification paradigm in prototypical GC and extrafollicular responses in mice. We next wanted to study 
how the frequencies of  memory B cells and PCs would relate to prototypical immune responses. Sev-
eral characteristics are known for extrafollicular and GC responses in mice (Figure 3A): extrafollicular 
responses are usually characterized by a high number of  PCs in the absence of  IgG+ memory B cells, 
whereas GC responses are characterized by class-switched PCs and memory B cells. We therefore wanted 
to test if  our classification method that we used in SLE patients can distinguish these responses based on 
frequencies of  antigen-specific B cells following immunization. We immunized wild-type C57BL/6 mice 
with the T-independent antigen 4-Hydroxy-3-nitrophenylacetyl-Ficoll (NP-Ficoll) and the T-dependent 
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antigen nitrophenylated– chicken γ globulin (NP-CGG). We analyzed NP-Ficoll–immunized mice at day 
7 and NP-CGG–immunized mice at day 7, 14, and 21. NP-Ficoll induces an extrafollicular response, and 
NP-CGG induces a T-dependent response with the generation of  PCs through a T-dependent extrafollicular 
pathway on day 7 and PC generation through the GC on day 14 and 21 (18–20). We analyzed antigen- 
specific NP+ IgG+ GC B cells, NP+ IgG+ non-GC B cells (“switched memory B cells”), and NP+ PCs (sep-
arated for cytoplasmic IgM and IgG) following immunization (Figure 3B). As expected, NP+ IgG+ GC B 
cells were present only following immunization with NP-CGG (Figure 3, C–F). The generation of  extrafol-
licular IgM and IgG NP+ PCs had similar kinetics with a peak of  NP+ PCs on day 7. To characterize each 
response with respect to the clusters we observed for ANA+ B cells in SLE patients, we analyzed the propor-
tions of  antigen-specific IgG+ non-GC (memory) cells, IgM+ PCs, and IgG+ PCs (Figure 3G). We observed 
that the pattern of  NP+ antigen-experienced cells in the extrafollicular response following NP-Ficoll (day 7) 
and NP-CGG (day 7) was characterized by a dominant PC phenotype, with only a few IgG+ memory B cells. 
Figure 1. Distinct phenotypes of ANA+ B cells and PC in SLE patients. (A–F) Frequencies of ANA+ and total B cell subsets in healthy controls (n = 15) and 
SLE patients (n = 36). Each dot indicates an individual, and the bars represent the median. *P < 0.05; **P < 0.01, using Mann-Whitney test. (G and H) 
Principal component analysis of all B cell parameters analyzed (frequencies of ANA+ and total B cell and PC subsets). The percentage indicated on the axis 
is the percentage of variance explained by that principal component. SLE patients were separated based on whether they displayed an increase in the fre-
quency of ANA+ IgG PCs compared with healthy controls (quartile 3 + 1.5 × interquartile range). Patients without expansion are denoted as “cluster 0.” (G) The 
variables contributing to each dimension in principal component analysis. The length and direction of each arrow shows the strength of their contribution 
to each PC. (H) The coordinates of each healthy individual and SLE patient. Ellipses represent the 95% confidence interval for each group. (I) Frequency 
of ANA+ IgG+ memory B cells and ANA+ PCs in SLE patients with an expansion of ANA+ PCs. Each dot indicates a patient (n = 22). (J) Relative proportion of 
ANA+ IgG memory B cells and ANA+ IgM and IgG PCs in healthy controls and SLE patients. The median and range of SLEDAI scores is shown below each 
circle. Patients were defined as “cluster 1” when their ANA+ PCs were >20% of the total ANA+ antigen-experienced cells (memory B cells and PCs). Patients 
were defined as “cluster 2” when their ANA+ PCs were <20% of the total ANA+ antigen-experienced cells. (K) Principal component analysis as in C and D, 
here only showing patients from cluster 1 and 2. ANA, antinuclear antibody; HC, healthy control; PC, plasmablast/plasma cell; SLE, systemic lupus erythe-
matosus; SLEDAI, SLE disease activity index.
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Figure 2. Stability of clustering over 
time. SLE patients were classified as 
described in Figure 1, and a follow-up 
was done between 1 month and 1 
year. (A) Relative proportion of ANA+ 
IgG memory B cells and ANA+ IgM 
and IgG PCs in healthy controls and 
SLE patients. The SLEDAI scores at 
the time of each measurement are 
shown below each circle. Patients 
indicated in red had a change in 
classification between the first and 
second assessment. (B) Principal 
component analysis as in Figure 1, 
including all initial measurements 
for healthy subjects and patients, 
was used to predict the follow-up 
measurements in each patient. 
Individual dots represent only those 
patients with a follow-up measure-
ment. Arrows indicate the follow-up 
measurement. Dotted black arrows 
indicate 2 patients (SLE 19 and SLE 
23) for whom the classification based 
on the proportions in A changed over 
time. ANA, antinuclear antibody; HC, 
healthy control; PC, plasmablast/
plasma cell; SLE, systemic lupus 
erythematosus; SLEDAI, SLE disease 
activity index.
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In contrast, the GC response on day 14 and 21 induced by immunization with NP-CGG was characterized 
by a major decrease in the ratio of  PCs to memory B cells. These data demonstrate that relative frequencies 
of  antigen-specific memory and PCs correlate with an extrafollicular or GC origin.
Classification of  memory B cells and PCs in lupus mice. As the frequencies of  memory B cells and PCs in a 
primary immunization are to a large degree defined by the kinetics of  the response, which do not necessarily 
display the same characteristics as a chronic autoimmune response, we next sought to analyze the relative 
frequencies of  autoreactive antigen-experienced cells in 2 well-studied lupus mouse models, MRL/lpr and 
NZB/W mice, with chronic B cell activation. Our previous data showed that both of  these mouse strains are 
characterized by increased frequencies of  ANA+ IgG PCs (2), similar to SLE patients. These mouse models 
are well known to have dominant G activation (NZB/W) or extrafollicular PC differentiation (MRL/lpr), 
respectively (14, 16, 21–23), NZB/W mice develop autoantibodies at a later time point than MRL/lpr mice 
(2). We therefore analyzed NZB/W mice before (age 3 months) and after (age 6 months) seroconversion to 
IgG anti-DNA reactivity to determine whether the pattern of  antigen- specific cells would change around the 
time that autoantibodies develop. Seropositive NZB/W mice had an increase in ANA+ IgG+ switched B cells 
coincident with a change in PC phenotype from IgM to IgG compared with young mice, which only had an 
increase in IgM+ PCs (Figure 4A). In contrast, the pattern of  ANA+ antigen- experienced cells in MRL/lpr 
mice was very distinct with a large increase in ANA+ PCs with only few IgG+ switched B cells. Although the 
relative frequency of  ANA+ IgM PCs in NZB/W mice was more than 20% of  antigen-experienced cells, the 
change at the time of  seroconversion from young to old mice showed a dominant ANA+ IgG+ memory B cell 
compared with PC frequency (Figure 4A, right circle).
These different frequencies of  ANA+ memory B cells and PCs are similar to what was observed following 
immunization with NP and analogous to what we observed in SLE patients.
Distinct IgG isotype usage, autoantibody affinity, and antigen recognition profiles characterize MRL/lpr versus 
NZB/W mice. IgG3 antibodies are characteristic of  T-independent extrafollicular responses (24, 25). We, 
therefore, explored IgG isotypes in ANA+ PCs from MRL/lpr and NZB/W mice and from mice immunized 
with NP-Ficoll and NP-CGG. There was an increase in the frequency of  ANA+ IgG3+ PCs in MRL/lpr mice 
compared with NZB/W mice (Figure 4, B–D). The IgG3 anti-dsDNA titer was also increased in MRL/lpr 
mice (Figure 4E), as has been reported in the literature (26, 27), consistent with the increase in ANA+ IgG3+ 
PCs we observed. The relative frequency of  IgG3 over the other IgG isotypes (IgG1, 2a/c, and 2b) was 
increased in MRL/lpr mice compared with NZB/W mice (Figure 4, F and G), a pattern that correlated with 
the T-independent response to NP-Ficoll (Figure 4, H and I).
We next asked whether our classification paradigm correlates to other parameters that can be mea-
sured in serum, in particular ones that could be studied in humans as well. If  the ANA+ PCs arise from 
different PC differentiation pathways in the 2 lupus-prone strains, we might expect to see a difference 
in affinity of  autoantibodies and the spectrum of  their specificities. We first determined the relative 
affinity of  anti-dsDNA antibodies by inhibition ELISA. We observed a higher IC50 in IgG anti-dsDNA 
from MRL/lpr mice compared with NZB/W mice, suggesting that the relative affinity in MRL/lpr mice 
is lower (Figure 5, A and C). Importantly, no difference was observed in the relative affinity of  IgM 
anti-dsDNA antibodies between the 2 strains (Figure 5, B and D). In addition to affinity and IgG sub-
class, we also analyzed the ANA specificity profile of  serum IgG and IgM, as extrafollicular antibodies 
may bind to a broader array of  antigens. We used hierarchical clustering to analyze whether a nonsuper-
vised clustering would independently show a difference between these strains. Antigen recognition by 
IgG from serum of  these lupus-prone mice clustered by strain (except for 1 NZB/W mouse) (Figure 5E), 
with IgG from MRL/lpr mice recognizing an increased number of  antigens compared with IgG from 
NZB/W mice (Figure 5F). In contrast, the IgM profile did not cluster by strain and the number of  anti-
gens recognized was comparable between the 2 strains of  mice (Figure 5, G and H).
Figure 3. Frequencies of memory B cells and PCs upon primary immunization in mice. (A) Model for differentiation of PCs. Two pathways can result in the 
differentiation of ANA+ IgG+ PCs, extrafollicular and germinal center, each leading to different proportions of IgG+ memory cells, IgM PCs, and IgG PCs. (B–G) 
C57BL/6 mice were immunized with NP-Ficoll or NP-CGG and analyzed at day 7, 14, and 21 after immunization. (B) Representative flow cytometry plots 
showing the frequency of NP+ cells among GC B cells, memory B cells, and PCs (the latter was analyzed upon cytoplasmic staining for NP). (C–F) Frequencies 
of NP+ GC B cells, NP+ memory B cells, NP+ IgM PCs, and NP+ IgG PCs. Each dot shows an individual mouse, and the bar represents the median. (G) Proportion 
of NP+ memory B cells and PCs These were calculated after subtracting the number of NP-specific cells in each population in unimmunized mice. Each pie 
chart shows the median for each strain (n = 4–6 mice per group). P values were calculated using χ2 test. ANA, antinuclear antibody; CGG, chicken γ globulin; 
FVD, fixable viability dye; GC, germinal center; NP, 4-hydroxy-3-nitrophenylacetyl; PC, plasmablast/plasma cell; SHM, somatic hypermutation.
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Together, these results suggest that the serum autoantibody response of  lupus mice correlates to the 
classification paradigm. IgG autoantibodies in MRL/lpr mice have characteristics of  an extrafollicular 
response (lower affinity, dominant IgG3 isotype, and broader antigen recognition profile), whereas the 
characteristics of  IgG autoantibodies in NZB/W mice are consistent with a GC origin (higher affinity, 
lower frequency of  IgG3, and more restricted antigen recognition profile). Interestingly, the IgM autoan-
tibodies in NZB/W mice were similar to those in MRL/lpr mice in both affinity and antigen recognition 
profile, which may suggest that the IgM ANA+ PCs, which are already present in young NZB/W mice, are 
of  extrafollicular origin and that these may be unrelated to the emergence of  IgG autoantibodies in older 
NZB/W mice that have characteristics of  a GC origin.
Serum autoantibody characteristics correlate to classification of  SLE patients. We next wanted to study whether 
autoantibody characteristics in SLE patients correlate to their classification, which may buttress the paradigm 
of a GC versus extrafollicular activation. We used hierarchical clustering to analyze whether a nonsupervised 
clustering would independently show a difference between the 2 clusters that we identified. When analyzing 
the ANA antigen specificity profile in serum IgG, we observed clustering of  patients in accordance with our 
classification (Figure 6A). Serum IgG from cluster 1 patients recognized significantly more nuclear antigens 
than IgG from cluster 2 patients, similar to the difference we observed between MRL/lpr and NZB/W mice 
(characterized by an extrafollicular and GC differentiation pathways, respectively) (Figure 6B). In addition, 
we previously reported increased total ANA-IgG levels in MRL/lpr mice compared with NZB/W mice (2). 
Consistent with our paradigm, patients from cluster 1 also had higher titers of  ANA-IgG in serum than 
patients in cluster 2 (Figure 6C). Likewise, although the number of  patients with sufficient titers of  anti- 
dsDNA to allow for determination of  affinity was low, we observed a trend toward higher affinity in the 
patients from cluster 2 (Figure 6, D and E).
Importantly, the serum characteristics (number of  nuclear antigens recognized and ANA-IgG titer) 
correlated most strongly with the relative proportion of  ANA+ PCs among ANA+ antigen-experienced B 
cells (Supplemental Figure 2, A and D), rather than the frequency of  ANA+ or total PCs (Supplemental 
Figure 2, B, C, E, and F), further confirming that the classification paradigm we developed here, rather than 
simply the number of  PCs, correlates to serum autoantibody characteristics and may thus correlate to an 
extrafollicular or GC response.
When including serology in the principal component analysis, the number of  nuclear antigens that 
were recognized as well as total ANA-IgG in serum went in the same direction as PC frequencies and 
maintained the patient clusters (Figure 6, F and G). There are a few exceptions. One patient without 
PC expansion overlapped with cluster 1 on the initial principal component analysis based on flow 
cytometry data (Figure 1H); this patient also overlapped with patients from cluster 1 when ELISA data 
were included in the principal component analysis, and the antigen recognition profile of  serum IgG 
resembled that of  cluster 1 patients. Another exception is patient SLE 23, who was classified in cluster 
2 in the first measurement but changed to cluster 1 upon a repeated measurement. Based on serology, 
this patient would classify as cluster 1. We did not include serology in the initial clustering, as serum 
was not available for all of  our patients.
Discussion
In this study we observed distinct phenotypes of  ANA+ antigen-experienced B cells in patients with 
SLE. We propose that these reflect 2 pathways for PC differentiation, an extrafollicular pathway and a 
GC pathway. The stratification we propose may be relevant to other diseases with ANA autoantibodies 
(such as Sjögren’s syndrome) or other autoantibodies, as several of  these are heterogeneous diseases 
that have ectopic B cell activation that can represent GC or extrafollicular responses as well (28).
The first group of  patients had no expansion of  ANA+ PCs compared with healthy controls. In 
addition, these patients clustered with healthy controls in principal component analysis. Several pos-
sible mechanisms could explain the absence of  an abnormal B cell profile in these patients: (a) lower 
disease activity; (b) medication; (c) absence of  current immune activation (there can be presence of  
autoantibody-producing PCs in the bone marrow without them being observed in the circulation); and 
(d) SLE pathogenesis caused by myeloid cell abnormalities rather than B cells. As we did not observe 
a lower disease activity or differences in medication of  this group compared with the other groups, 
option 1 and 2 seem unlikely. Because these patients did not show any B cell abnormalities compared 
with healthy controls, we have not further analyzed them in this study.
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Figure 4. Frequencies of ANA+ memory B cells and PCs in MRL/lpr and NZB/W mice. (A–G) Splenocytes from MRL/lpr and NZB/W mice were stained 
with nuclear extract to analyze the percentage of ANA+ B cells. Each dot indicates an individual mouse (n = 5–8 for each group), and the bars represent the 
median. (A) Proportion of ANA+ antigen-experienced cells in the spleens of each mouse strain. NZB/W “Change during seroconversion” was calculated by 
subtracting the maximal measurements in young mice (quartile 3 + 1.5 × interquartile range) from the measurements in old mice. (B–D) The frequencies of 
total and ANA+ IgG3+ PCs. (E) dsDNA-reactive IgG3 in serum of MRL/lpr and NZB/W mice was determined by ELISA. (F and G) The relative number of IgG3+ 
and IgG1/2+ cells within the population of IgG ANA+ PCs of MRL/lpr and NZB/W mice. (H and I) The relative number of IgG3+ and IgG1/2+ cells within the 
population of IgM– NP+ PCs of C57BL/6 mice immunized with NP-Ficoll (day 7) and NP-CGG (day 7 and day 21). *P < 0.05; **P < 0.01; ***P < 0.001, using 
χ2 test (A), Mann Whitney U test (B–E), or 2-way ANOVA with Bonferroni post-hoc test (G and I). ANA, antinuclear antibody; CGG, chicken γ globulin; NP, 
4-hydroxy-3-nitrophenylacetyl; PC, plasmablast/plasma cell.
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The second group of  SLE patients (cluster 1) was characterized by a large number of  ANA+ PCs 
and reduced memory B cells, whereas the other group of  patients (cluster 2) had a lower frequency 
of  ANA+ PCs (although still higher than healthy controls) and a higher frequency of  ANA+ memory 
B cells. Importantly, the clustering was not dependent on SLEDAI scores and was stable over time in 
the vast majority of  patients, suggesting a way to subset SLE patients that is independent from disease 
activity. Similar frequencies (~20%) of  patients with a plasmablast signature were found in another 
study of  gene expression in pediatric SLE patients (29). This novel approach may have therapeutic 
implications. Although patients in cluster 1 were more frequently on steroids, this medication is asso-
ciated with lower plasmablast gene signatures in blood (29) and reduces PC differentiation in vitro 
(30). Therefore, the phenotype we observed in cluster 1 (high frequency of  ANA+ PCs) is unlikely to 
be the consequence of  treatment with steroids. It may be possible that patients in cluster 1 had a more 
intense medication scheme due to more cumulative disease activity (over the past few years) that was 
Figure 5. Characteristics of serum autoantibodies in lupus mice. (A–D) Relative affinity of anti-dsDNA IgG and IgM was measured in serum of MRL/lpr 
and NZB/W mice by inhibition ELISA. (A and B) Relative OD (average ± SEM) of each strain. (C and D) IC50 values for each individual mouse. (E–H) Profiles 
of recognition of nuclear antigens by serum IgG (E and F) and IgM (G and H). (E and G) Heatmaps, including hierarchical clustering based on the profile of 
antigen recognition. (F and H) The number of nuclear antigens recognized. Each dot indicates an individual mouse (n = 6–9 for each group), and the bars 
represent the median. *P < 0.05; **P < 0.01, using Mann Whitney U test. ANA, antinuclear antibody; cyto, cytoplasmic; PC, plasma cell; SS-A/B, anti–
Sjögren’s syndrome–related antigen; Sm, Smith antigen.
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Figure 6. Characteristics of serum autoantibodies in SLE patients. (A and B) Profiles of recognition of nuclear antigens by serum IgG. Patients are 
separated based on classification, as described in Figure 1, into cluster 1 and cluster 2. (A) Heatmap, including hierarchical clustering based on the profile 
of antigen recognition. Blocks that show 2 colors represent the patients in which the classification changed over time (Figure 2), in which case the top 
left triangle represents the classification in the first measurement and the lower right represents the classification in the second measurement. (B) The 
number of nuclear antigens recognized. Each dot indicates an individual patient, and the bars represent the median. (C) Total ANA-IgG was determined 
by ELISA. (D and E) Relative affinity of anti-dsDNA IgG was measured in serum of SLE patients by inhibition ELISA. (D) Relative OD (average ± SEM) of 
each group is shown. (E) IC50 values for each individual patient. (F and G) Principal component analysis of all parameters analyzed (frequencies of ANA+ 
and total B cell and PC subsets as well as ELISA recognition of nuclear antigens). The percentage indicated on the axis is the percentage of variance 
explained by that principal component. A selection of the vectors for direction of parameters is shown here. The parameters omitted here (ANA+ and 
total transitional and naive B cells) are shown in Figure 1G. Their directionality remained the same. SLE patients were clustered as described in Figure 1. 
(F) The variables contributing to each dimension in principal component analysis. The length and direction of each arrow shows the strength of their 
contribution to each PC. (G) The coordinates of each SLE patient. Ellipses represent the 95% confidence interval for each group. *P < 0.05, using Mann 
Whitney U test. ANA, antinuclear antibody; PC, plasmablast/plasma cell; SS-A/B, anti–Sjögren’s syndrome–related antigen; Sm, Smith antigen; SLE, 
systemic lupus erythematosus.
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not directly reflected in current activity scores or clinical symptoms. This could also be related to a 
higher probability of  patients in cluster 1 to experience clinical flares. A larger patient cohort with 
longitudinal data would be needed to confirm this.
We have correlated the relative frequencies of  antigen-specific cells we observed in SLE patients to 
those in mice after primary immunization and in mice with lupus. The pattern we observed in patients 
from cluster 1 was comparable to extrafollicular immune activation during a primary immunization and 
to the pattern in MRL/lpr mice. The pattern we observed in patients from cluster 2 was comparable 
to GC immune activation and to the pattern in NZB/W mice. These data suggest that ANA+ PCs in 
patients from cluster 1 derive from an extrafollicular pathway, whereas those in patients from cluster 
2 may derive from a GC response. Importantly, the difference in several serum autoantibody charac-
teristics (ANA titer, number of  different antigens recognized, and affinity) between patients from each 
cluster further strengthens this notion. Literature suggests that extrafollicular autoreactive responses are 
characterized by higher autoantibody titers with lower affinity (31). Importantly, both extrafollicular 
and GC-derived autoantibodies led to similar kidney deposition and pathogenesis. This is in line with 
the data we present here in which patients from each cluster have comparable SLEDAI scores and renal 
involvement. Therefore, we believe that both extrafollicular and GC PC differentiation can lead to 
disease pathogenesis in SLE (32) and that our classification represents a simple way to stratify patients 
with respect to these pathways.
GC responses are well known to be increased in lupus-prone mice, and SLE patients often have increased 
numbers of  circulating pre-GC B cells, switched memory B cells, and Tfh cells, suggestive of  enhanced GC 
responses (8–10). Given that IgG anti-DNA autoantibodies that are considered to be pathogenic in SLE show 
evidence of  SHM and often a loss of  autoreactivity when reverted to the germline sequence (11), the pro-
duction of  autoreactive PCs by SHM of nonautoreactive naive B cells within the GC has been considered 
an important contributor to the development of  SLE in both mice (12) and humans (13). Recent studies 
indicate the extrafollicular pathway also has a role in autoimmunity (6, 14, 15, 33). MRL/lpr mice exhibit 
extrafollicular PC generation, although they have increased formation of  spontaneous GCs as well (8, 14, 16). 
Consistent with our results, two elegant studies by Sanz and colleagues have shown that activated naive B cells 
and age-associated B cells (ABCs) (designated DN2 in their study) can be clonally related to circulating PCs in 
SLE patients with active flares, and these may therefore derive from extrafollicular pathways (6, 33). In addi-
tion, Ettinger and colleagues have also shown a correlation of  ABCs with disease activity, and in each study, 
the population also correlates with the frequency of  PCs in SLE (34). Therefore, the extrafollicular pathway 
can be related to disease pathogenesis. However, the correlation to disease activity and PC frequencies is only 
evident when analyzing large patient numbers and is not dichotomous: Several patients have a high frequency 
of  these cell subsets with a low disease activity and vice versa, suggesting that multiple pathways for disease 
pathogenesis exist. While neither group specifically proposed 2 pathways of  PC differentiation, their data are 
consistent with the dichotomy we propose. Of the 5 patients Sanz and colleagues analyzed for activated naive 
cells, 2 exhibited more clonal relationships between PCs and naive cells, whereas the 3 other patients exhibited 
more clonal relationships between PCs and memory cells (6). Of the 8 patients they analyzed for switched 
ABCs, 3 had more clonal relationships between PCs and ABCs, whereas 4 had more clonal relationships 
between PCs and memory cells, and 1 additional patient had a comparable frequency of  clonal relationships 
of  PCs to ABCs and memory B cells (33). As they study primarily patients during a clinical flare, they may be 
observing a T-dependent response during the time of  extrafollicular B cell activation prior to the GC response 
(Figure 1G). In any case, these data are in line with our hypothesis that SLE patients cluster in 2 groups based 
on distinct PC differentiation pathways that can be observed in circulating PCs.
Several studies have attempted to stratify SLE patients, most using gene expression profiles of  
peripheral leukocytes or subsets thereof, such as T cells or neutrophils (29, 35–37). Most of  these studies 
have focused on correlations with disease activity or clinical symptoms, such as nephritis. These studies 
revealed correlations of  plasmablast signatures and IFN signatures with disease activity in pediatric 
patients (29) and correlations of  neutrophil signatures with lupus nephritis (29, 36). Two of  these studies 
proposed stratification schemes based on the correlations of  molecular parameters with SLEDAI score. 
In each scheme, the assignment of  an individual patient to a cohort required longitudinal data (29, 36). 
Importantly, the correlations of  specific groups of  genes or signatures with disease activity suggest that 
different molecular pathways can contribute to active disease in patient groups, similar to what we pro-
pose here with respect to plasmablast derivation.
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We believe the most important question is whether any proposed classification can identify those 
patients most likely to respond to a given therapeutic agent. Although providing novel insights into the 
heterogeneity of  SLE, the stratifications proposed in the studies mentioned above often require multiple 
longitudinal measurements to determine patient clusters (29, 36), thereby limiting their applicability for 
stratifying patients going into clinical trials. While we currently cannot answer the question whether our 
classification will predict a response to particular therapy, this question can be addressed by using our 
methodology to analyze patients entering clinical trials with the methods we present. It is interesting 
to note that the mouse strains that we have described differ in their response to anti-IFN therapy, even 
though both strains have an IFN signature (38–40). It is likely that some therapeutic agents will prefer-
entially target the GC PC differentiation pathway, while others will target the extrafollicular pathway. 
Classification of  SLE patients by their PC differentiation pathway and then treating with an agent 
targeting that pathway should maximize the therapeutic response to a given agent and brings precision 
medicine to the lupus clinic.
Methods
Mice. C57BL/6, NZB/W F1, and MRL/lpr female mice were purchased from The Jackson Laboratory. 
Two- to six-month-old lupus-prone mice and age-matched controls were sacrificed at the time points indi-
cated in Results, and bone marrow and spleens were obtained. For NP immunizations, C57BL/6 mice were 
immunized i.p. with 50 μg NP-AECM-Ficoll (at a conjugation ratio of  55:1) (Biosearch Technologies) in 
saline or with 100 μg NP-CGC (at a conjugation ratio of  20:1) (Biosearch Technologies) in alum (Thermo 
Fisher), after which spleens were obtained at day 7, 14, and 21. Single-cell suspensions were obtained from 
these tissues by standard procedures, and red blood cells were lysed using RBC lysis buffer (Biolegend). 
Serum from lupus-prone mice and their age-matched controls was obtained by submandibular bleeding.
SLE patients and healthy subjects. Blood from 36 SLE patients and 15 healthy subjects was collected 
in heparinized tubes, and PBMCs were obtained using standard Ficoll procedure. SLE diagnosis was 
based on 1997 revised ACR criteria (41). SLE patients receiving rituximab, belimumab, or cyclophos-
phamide in the preceding 12 months for the initial assessment were excluded from the study. One 
patient (SLE 32) used cyclophosphamide at the repeat measurement. At the time of  the blood draw, all 
SLE patients were assessed for disease activity using the SLEDAI-2K (42). Patient characteristics are 
shown in Supplemental Tables 1 and 2.
Flow cytometry for ANA+ B cells. Nuclear extract from HeLa cells was obtained as described previously 
(1). Briefly, nuclei from HeLa cells were isolated using the Nuclei EZ lysis kit (MilliporeSigma), frag-
mented by vortexing with 0.5-mm cell disruption glass beads (Scientific Industries), and biotinylated using 
EZ-Link-Sulfo-NHS-LC-biotin (Thermo Scientific). Staining for ANA+ B cells was done as described pre-
viously (2). Briefly, cells were incubated with biotinylated nuclear extract in HBSS + 1.5% nonfat dry 
milk (LabScientific) for 30 minutes on ice. After thorough washing, cells were stained in HBSS + 2% FBS 
containing 1 μg/ml streptavidin-APC (Life Technologies) and cell surface antibodies. eFluor 506–labeled 
fixable viability dye (eBioscience) was added during staining with cell surface antibodies. For intracellular 
staining, cells were fixed and permeabilized with the Transcription Factor Staining Buffer Set (eBioscience) 
according to the manufacturer’s instructions. After permeabilization, cells were stained in 1.5% nonfat dry 
milk (LabScientific) dissolved in permeabilization buffer with nuclear extract followed by streptavidin and 
anti-Ig antibodies dissolved in permeabilization buffer as described above.
The following anti-mouse antibodies were used: IgG1-FITC and -BV605 (clone A85-1), IgG2a,b-FITC and 
-BV605 (clone R2-40), IgG3-FITC and -BV605 (clone R40-82), IgD-PE (clone 11-26c.2a), and CD95-PECy7 
(clone Jo2) (all from BD Biosciences); B220-PE-eF610 (clone RA3-6B2), IgM-eFluor450 (clone II/41), and 
GL7-FITC (clone GL7) (all from eBioscience); and CD3-BV510 (clone 17A2), CD19-BV711 (clone 6D5), and 
CD138-PE or -PerCpCy5.5 (clone 281-2) (all from Biolegend).
For staining of  NP-specific B cells in immunized mice, NP-BSA-biotin (at a conjugation ratio of  6:1) 
(Biosearch Technologies) was preincubated for 30 minutes with streptavidin-APC in a 1:1 molar ratio, after 
which cells were incubated with 0.1 μg/ml NP-BSA-biotin + streptavidin-APC.
The following anti-human antibodies were used: IgG-FITC (G18-145, BD Biosciences); CD3-eF506 
(UCHT1), CD14-eF506 (61D3), CD56-eF506 (TULY56), CD20-eF450 (2H7), CD38-PE-eF610 (HIT2), 
and CD27-PE (0323) (all from eBioscience); and CD19-PECy7 (HIB19) and IgM-PerCpCy5.5 (MHM-88) 
(both from Biolegend).
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Flow cytometric acquisition was performed on Fortessa (BD). Analysis was performed using FACS 
Diva (BD) and FlowJo software.
We previously published the gating of  our mouse and human B cell subsets (2). Briefly, gating was 
as follows for human B cells: transitional B cells were Dump– (FVD/CD3/CD14/CD56) CD19+C-
D38++CD27–IgM++; naive B cells were Dump–CD19+CD38+CD27–IgM+/–IgG–; IgM+CD27+ cells were 
Dump–D19+CD38+/–CD27+IgM+IgG–; IgG+ memory cells were Dump–CD19+CD38+/–CD27+IgM–
IgG+ and IgM+; and IgG+ PCs were Dump–CD19+CD20–CD27++CD38++ and cytoplasmic IgM+IgG– 
or IgG+IgM–, respectively. Gating was as follows for mouse B cells: switched mIgG+ B cells were 
FVD–mIgG1/2a,b+mIgM–; IgG GC B cells were FVD–B220+IgG+GL7++CD95+; IgG non-GC B cells 
were FVD–B220+IgG+GL7–; IgM+ PCs were FVD–B220loCD138+cIgM++cIgG–; and IgG+ PCs were 
FVD–B220loCD138+cIgG++cIgM–.
ELISA. Half-area 96-well ELISA plates (Corning) were coated with 400 μg/ml sonicated filtered 
calf-thymus DNA (Calbiochem). For analysis of  binding to separate nuclear antigens, coated plates from 
the anti-ENA SLE profile-2 ELISA (Euroimmun) were used, combined with detection using AP-labeled 
anti-mouse IgM, IgG, or anti-human IgG (Southern Biotech). For analysis of  total ANA-IgG titers in 
human samples, the Quanta Lite ANA ELISA (Inova diagnostics) was used, combined with detection 
using AP-labeled anti-human IgG (Southern Biotech).
Washing steps were performed with 0.05% Tween20 (Fisher) in PBS (Invitrogen). Plates were blocked 
with 1% BSA fraction V (Roche) in PBS for 1 hour at 37°C. Samples were diluted in 0.2% BSA in PBS, 
and incubated for 1.5 hours at 37°C. Serum samples were diluted ×40–×400 (depending on manufacturer’s 
instructions). After washing, 1 μg/ml alkaline phosphatase–labeled goat anti-mouse IgM, total IgG, or 
IgG3 (Southern Biotech) was incubated for 1 hour at 37°C. For detection, 1 mg/ml phosphatase substrate 
(MilliporeSigma) was dissolved in substrate buffer (50 mM NaHCO3, 1 mM MgCl2; MilliporeSigma) for 
detection. The plates were read at 405 nm on a 1430 Multilabel Counter Spectrometer (PerkinElmer).
For inhibition ELISA to determine relative affinities of  anti-dsDNA, plates were coated with 1 μg/ml 
calf  thymus dsDNA (43). The EC50 was first established for each serum by performing serum titrations to 
ensure that the inhibition ELISA was performed in a linear range of  the serum dilution. Subsequently, serum 
was diluted to the concentration equivalent to the EC50 and mixed with dsDNA, in 3-fold dilutions ranging 
from 5 to 0.0068 μg and 1 condition containing no dsDNA.
Statistics. Unless indicated otherwise, P values of  less than 0.05 were considered statistically significant. 
Each experiment was performed at least twice to ensure reproducibility. For comparison of  groups of  mice 
or subjects, the Mann Whitney U test (2 tailed) was used. To compare frequencies, χ2 test and Fisher exact 
test were used as indicated. To determine IC50 values for inhibition ELISAs, normalized OD values were 
calculated based on the maximum OD values when no inhibitor was present. Nonlinear regression [log(ag-
onist) vs. response – variable slope] was used to interpolate the IC50 values at Y = 0.5. Correlations were 
calculated using Spearman’s rank correlation.
Principal component analysis was performed using flow cytometry and ELISA data. Briefly, parameters 
were log transformed, scaled, and centered, after which principal components were calculated using prcomp. 
Principal components were visualized using the FactoExtra package. Heatmaps from ELISA data were gen-
erated using log-transformed OD values in the heatmap function. Heatmaps were scaled by column.
Statistical analysis was performed using GraphPad Prism 5 and R Studio 1.1.
Study approval. Mice were housed in according to AAALAC regulations, and all mouse studies were 
approved the Institutional Animal Care and Use Committee of  the Feinstein Institute for Medical Research. 
The study with SLE patients and healthy subjects was approved by the Northwell Health Institutional 
Review Board, and all subjects gave written informed consent.
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